BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a ...

Additionally, Dyne will highlight its FORCE™ platform, which is designed to deliver targeted therapies to muscle and the central nervous system. The conference presentations will be complemented ...

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 ...

including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the potential of DYNE-101 and DYNE-251 ...

Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report issued on ...

including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the potential of DYNE-101 and DYNE-251 ...

When Might Dyne Therapeutics Run Out Of Money? A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Dyne Therapeutics last reported its December 2024 balance ...

Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping The FORCE™ Platform Achieves Robust and Durable DUX4 Suppression and ...

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.